Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116745 | 0.80 | CA1 (0.34) | CA1CA2APLNRSIGMAR1 | |
| SCHEMBL116744 | 0.80 | CA1 (0.34) | CA1CA2APLNRSIGMAR1 | |
| SCHEMBL4072449 | 0.78 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL5301444 | 0.77 | GABRA1 (0.43) | CA1CA2LMNAMAPTGPR55 | |
| SCHEMBL27692683 | 0.75 | CA1 (0.37) | CA1CA2APLNRSIGMAR1MEN1 | |
| SCHEMBL24645032 | 0.74 | CA1 (0.36) | CA1CA2APLNRSIGMAR1FLT1 | |
| SCHEMBL1854753 | 0.74 | CA1 (0.36) | CA1CA2APLNRSIGMAR1MEN1 | |
| SCHEMBL1854756 | 0.74 | CA1 (0.36) | CA1CA2APLNRSIGMAR1MEN1 | |
| SCHEMBL16793738 | 0.74 | LMNA (0.41) | CA1CA2APLNRSIGMAR1MEN1 | |
| SCHEMBL12248175 | 0.74 | CA1 (0.36) | CA1CA2SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424865-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2017-01-18 | — | — | EP | disclosed |
| EP-2687525-B1 | CYCLIC INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-8680093-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2687525-A1 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | Boehringer Ingelheim International GmbH (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-8629138-B2 | — | — | 2014-01-14 | — | — | US | disclosed |
| US-8575157-B2 | — | — | 2013-11-05 | — | — | US | disclosed |
| EP-2324018-B1 | CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-04 | — | — | EP | disclosed |
| US-8114868-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-02-14 | — | — | US | disclosed |
| US-8114868-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-02-14 | — | — | US | disclosed |
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2011-01-13 | — | — | US | disclosed |
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD11B2, HSD3B1 | CA1 1069/4885CA2 608/4885APLNR 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.